Developer docs
API playgroundTry for free, no card

Search company profiles

Behold.ai

Full company profile

uuid0002jgq

Namestring
Behold.ai
Legal namestring
Behold.ai Global Technologies Limited
Websiteurl
behold.ai
Company typeenum
Private
Founded yearint
2017
Short descriptiontext

Behold.ai provides the red dot® AI platform for autonomous radiology diagnosis across chest X-ray (lung cancer detection) and CT head (stroke triage), serving NHS Trusts in the UK, Apollo Hospitals in India, and US systems via Merative.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI radiology diagnostics, medical imaging software, chest x-ray analysis, CT head triage, radiology workflow automation
Industry3 codes
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
AI Radiology Diagnostics Software
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Per Exam Pricing
TypeUsage Based
Description

The company charges on a per exam basis for the red dot® algorithm triage and instant triage services, particularly for the FDA-cleared pneumothorax detection functionality.

behold.ai
2NHS Framework / Contract Revenue
TypeSubscription Recurring
Description

Approved for NHS Share Business Framework with Phase 4 AI Award winner for national rollout. Revenue generated through NHS trust contracts for the lung cancer detection platform.

behold.ai
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Per exam pricing model for AI triage services
ModelUsage-basedBilling cadencePay-as-you-go
Notes

The company charges on a per exam basis for the instant triage functionality, particularly for the FDA-cleared pneumothorax detection. Specific pricing not publicly disclosed.

behold.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1red dot®
Description

Award-winning AI-powered diagnostic platform for CT and X-ray imaging designed for rapid and accurate detection of critical conditions such as lung cancer and stroke. The platform includes red dot® Lung Cancer Detection Platform (for chest X-rays) and red dot® CTH V1 (for CT head examinations).

behold.ai
Core offering1 text field

Behold.ai develops and sells the red dot® AI-powered diagnostic platform — a Software as a Medical Device that processes chest X-rays and CT head scans to automatically identify normal examinations and triage suspected critical findings (lung cancer, intracranial haemorrhage, acute infarct, pneumothorax). The platform is sold to NHS Trusts in the UK via direct sales and NHS framework contracts, and internationally through channel partners Merative (US) and Apollo Hospitals (India).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 71% reduction in average time from CXR to CXR report (from 7 days to 2 days)
+6 more records
Product overview1 text field

Behold.ai offers the red dot® AI-powered diagnostic platform for CT and X-ray imaging. The platform comprises two core products: the red dot® Lung Cancer Detection Platform for chest X-ray analysis and the red dot® CTH V1 for CT head examinations. Both products leverage the same proprietary AI algorithm to provide rapid, autonomous diagnosis that identifies normal examinations for auto-reporting and flags urgent findings for prioritization. The platform integrates seamlessly with existing hospital RIS and PACS systems and has demonstrated robust clinical validation with zero missed lung cancers over three years using the Rule-Out AI functionality.

Product and service3 records
1red dot® Lung Cancer Detection Platform
CategoryAI Radiology Diagnostics Software
Description

FDA-cleared and CE-marked AI platform that automatically identifies normal adult (18+) frontal chest X-rays and triages potential lung cancer cases for faster clinical decision-making, returning results within 30 seconds with heatmap visualization.

2red dot® CTH V1
CategoryAI Radiology Diagnostics Software
Description

AI-powered CT Head algorithm enabling 24/7 triage of acute findings and rule-out of normal CT head examinations. Identifies intracranial haemorrhage (ICH) and acute infarct within 5 minutes, prioritizing patients for urgent care.

3red dot® V2 Clinical Analysis Software
CategoryAI Radiology Diagnostics Software
Description

Updated version of the red dot® AI platform that autonomously rules out normal patients presenting for chest X-ray in 7 seconds and identifies priority suspected lung cancer cases in combination with radiologists.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Wellbeing Software
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-03-31
Description

Collaboration on national solution for rapid COVID-19 diagnosis using AI analysis of chest X-rays. Wellbeing Software operates Cris, the UK's most widely used Radiology Information System (RIS), installed in over 700 locations. Integration enables fast-track national rollout across NHS hospitals.

behold.ai
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-03-18
Description

Partnership for rapid COVID-19 diagnosis using AI-based chest X-ray technology. World's largest deployment of radiology-based AI diagnostic solution for COVID-19. Deployed in Apollo's network of 71 hospitals in India with 12,000 beds. Analyzed 82,093 CXR exams over 19 months.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

US distribution partnership where Merative distributes red dot® AI radiology solutions. Merative has over 23% of PACS imaging systems market share in the US, providing significant market access for Behold.ai's FDA-cleared pneumothorax triage product.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

AWS initiative supporting the Apollo Hospitals partnership for COVID-19 diagnostic development. The initiative accelerates research and innovation on COVID-19 and infectious diseases through early disease detection, diagnostics, prognosis and public health genomics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Government funding through the AI in Health and Care Award Phase 4. Award provides funding for set-up of clinical trials sites in NHS radiology departments and supports initial national adoption. One of 38 organisations to receive funding under the NHS Long Term Plan AI initiatives.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Behold.ai is an approved supplier on the NHS Share Business Framework, enabling direct procurement by NHS Trusts across England for the red dot® lung cancer detection platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in AI-powered radiology for chest X-ray and CT head, with FDA-cleared products for head CT, chest CT, and chest X-ray. Most directly comparable peer given similar product focus and target customers (hospitals globally).

TypeDirect peer
Description

AI imaging company specializing in stroke and CT/MRI brain analysis with care coordination workflow. Comparable peer for CT head triage and neurology-focused clinical pathways.

TypeDirect peer
Description

AI platform focused on CT head for stroke detection (large vessel occlusion) and care coordination. Directly comparable for the red dot CTH V1 stroke/triage use case, with similar FDA clearance pathway and hospital sales motion.

TypeDirect peer
Description

Radiology AI platform covering chest X-ray and CT head with autonomous reporting capabilities, FDA and CE cleared. Closely comparable in regulatory positioning and product scope.

TypeDirect peer
Description

Korean AI company developing radiology AI for chest X-ray (Lunit INSIGHT CXR) with FDA clearance and CE mark. Direct peer with similar focus on lung nodule/cancer detection and global hospital customer base.

TypeDirect peer
Description

Broad radiology AI platform with FDA-cleared algorithms for CT head (haemorrhage, stroke) and other acute findings. Direct peer in CT head triage and broader hospital radiology AI market.

7Nanox (formerly Zebra Medical Vision)
TypeDirect peer
Description

Broad radiology AI platform with multiple FDA-cleared algorithms covering chest, bone, and other findings. Comparable peer in AI radiology commercialization model and hospital sales approach.

8Announcement: iCAD (ProFound AI)
TypeBroad incumbent
Description

Medical imaging AI vendor focused on mammography and CT with FDA-cleared products. Comparable incumbent in radiology AI commercialization with regulatory depth and clinical evidence.

TypeBroad incumbent
Description

Owns 23%+ US PACS imaging market share and distributes Behold.ai's pneumothorax product. Established PACS vendor and channel partner that could also compete with embedded AI capabilities.

TypeBroad incumbent
Description

Major imaging equipment vendor with embedded AI-Rad Companion platform for chest CT and other modalities. Broad incumbent that competes by integrating AI directly with installed imaging equipment base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Behold.ai

AI Radiology Diagnostics Softwarebehold.ai

Behold.ai provides the red dot® AI platform for autonomous radiology diagnosis across chest X-ray (lung cancer detection) and CT head (stroke triage), serving NHS Trusts in the UK, Apollo Hospitals in India, and US systems via Merative.

Behold.ai firmographics

Firmographics
Name
Behold.ai
Legal name
Behold.ai Global Technologies Limited
Website
https://behold.ai
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Behold.ai provides the red dot® AI platform for autonomous radiology diagnosis across chest X-ray (lung cancer detection) and CT head (stroke triage), serving NHS Trusts in the UK, Apollo Hospitals in India, and US systems via Merative.
Ownership category
akta.pro rank

Behold.ai industry classification

Industry
Product category
AI Radiology Diagnostics Software
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability

Keywords

  • AI radiology diagnostics
  • Medical imaging software
  • Chest x-ray analysis
  • CT head triage
  • Radiology workflow automation

Where Behold.ai is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Behold.ai business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Per Exam Pricing: The company charges on a per exam basis for the red dot® algorithm triage and instant triage services, particularly for the FDA-cleared pneumothorax detection functionality.
  2. NHS Framework / Contract Revenue: Approved for NHS Share Business Framework with Phase 4 AI Award winner for national rollout. Revenue generated through NHS trust contracts for the lung cancer detection platform.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goPer exam pricing model for AI triage services

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Behold.ai product offering

Product offering

Core offering

Behold.ai develops and sells the red dot® AI-powered diagnostic platform — a Software as a Medical Device that processes chest X-rays and CT head scans to automatically identify normal examinations and triage suspected critical findings (lung cancer, intracranial haemorrhage, acute infarct, pneumothorax). The platform is sold to NHS Trusts in the UK via direct sales and NHS framework contracts, and internationally through channel partners Merative (US) and Apollo Hospitals (India).

Product overview

Behold.ai offers the red dot® AI-powered diagnostic platform for CT and X-ray imaging. The platform comprises two core products: the red dot® Lung Cancer Detection Platform for chest X-ray analysis and the red dot® CTH V1 for CT head examinations. Both products leverage the same proprietary AI algorithm to provide rapid, autonomous diagnosis that identifies normal examinations for auto-reporting and flags urgent findings for prioritization. The platform integrates seamlessly with existing hospital RIS and PACS systems and has demonstrated robust clinical validation with zero missed lung cancers over three years using the Rule-Out AI functionality.

Differentiator

Problem solved

Functional benefit

Brands

  • red dot®: Award-winning AI-powered diagnostic platform for CT and X-ray imaging designed for rapid and accurate detection of critical conditions such as lung cancer and stroke. The platform includes red dot® Lung Cancer Detection Platform (for chest X-rays) and red dot® CTH V1 (for CT head examinations).

Products and services

  • red dot® Lung Cancer Detection Platform FDA-cleared and CE-marked AI platform that automatically identifies normal adult (18+) frontal chest X-rays and triages potential lung cancer cases for faster clinical decision-making, returning results within 30 seconds with heatmap visualization.
  • red dot® CTH V1 AI-powered CT Head algorithm enabling 24/7 triage of acute findings and rule-out of normal CT head examinations. Identifies intracranial haemorrhage (ICH) and acute infarct within 5 minutes, prioritizing patients for urgent care.
  • red dot® V2 Clinical Analysis Software Updated version of the red dot® AI platform that autonomously rules out normal patients presenting for chest X-ray in 7 seconds and identifies priority suspected lung cancer cases in combination with radiologists.

Quantifiable outcome

  • 71% reduction in average time from CXR to CXR report (from 7 days to 2 days)
  • +6 more outcomes

Companies that use Behold.ai

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Behold.ai technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature5 records

Behold.ai partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and supporting.

  • Wellbeing SoftwarecoreTechnology or Integration · 31 March 2020Collaboration on national solution for rapid COVID-19 diagnosis using AI analysis of chest X-rays. Wellbeing Software operates Cris, the UK's most widely used Radiology Information System (RIS), installed in over 700 locations. Integration enables fast-track national rollout across NHS hospitals.
  • Apollo Hospitals Group / Apollo Radiology InternationalcoreChannel Partner/ Reseller/ Distributor · 18 March 2020Partnership for rapid COVID-19 diagnosis using AI-based chest X-ray technology. World's largest deployment of radiology-based AI diagnostic solution for COVID-19. Deployed in Apollo's network of 71 hospitals in India with 12,000 beds. Analyzed 82,093 CXR exams over 19 months.
  • MerativecoreChannel Partner/ Reseller/ DistributorUS distribution partnership where Merative distributes red dot® AI radiology solutions. Merative has over 23% of PACS imaging systems market share in the US, providing significant market access for Behold.ai's FDA-cleared pneumothorax triage product.
  • Amazon Web Services (AWS) Diagnostic Development InitiativesupportingStrategic or Co-development PartnerAWS initiative supporting the Apollo Hospitals partnership for COVID-19 diagnostic development. The initiative accelerates research and innovation on COVID-19 and infectious diseases through early disease detection, diagnostics, prognosis and public health genomics.
  • NHSX / Accelerated Access CollaborativecoreStrategic or Co-development PartnerGovernment funding through the AI in Health and Care Award Phase 4. Award provides funding for set-up of clinical trials sites in NHS radiology departments and supports initial national adoption. One of 38 organisations to receive funding under the NHS Long Term Plan AI initiatives.
  • NHS Share Business Services AuthoritycoreImplementation/ SI/ Consulting PartnerBehold.ai is an approved supplier on the NHS Share Business Framework, enabling direct procurement by NHS Trusts across England for the red dot® lung cancer detection platform.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Behold.ai competitors and assessment

Company assessment

Direct peers

  • Qure.ai: Direct competitor in AI-powered radiology for chest X-ray and CT head, with FDA-cleared products for head CT, chest CT, and chest X-ray. Most directly comparable peer given similar product focus and target customers (hospitals globally).
  • RapidAI: AI imaging company specializing in stroke and CT/MRI brain analysis with care coordination workflow. Comparable peer for CT head triage and neurology-focused clinical pathways.
  • Viz.ai: AI platform focused on CT head for stroke detection (large vessel occlusion) and care coordination. Directly comparable for the red dot CTH V1 stroke/triage use case, with similar FDA clearance pathway and hospital sales motion.
  • Annalise.ai: Radiology AI platform covering chest X-ray and CT head with autonomous reporting capabilities, FDA and CE cleared. Closely comparable in regulatory positioning and product scope.
  • Lunit: Korean AI company developing radiology AI for chest X-ray (Lunit INSIGHT CXR) with FDA clearance and CE mark. Direct peer with similar focus on lung nodule/cancer detection and global hospital customer base.
  • Aidoc: Broad radiology AI platform with FDA-cleared algorithms for CT head (haemorrhage, stroke) and other acute findings. Direct peer in CT head triage and broader hospital radiology AI market.
  • Nanox (formerly Zebra Medical Vision): Broad radiology AI platform with multiple FDA-cleared algorithms covering chest, bone, and other findings. Comparable peer in AI radiology commercialization model and hospital sales approach.

Broad incumbents

  • Announcement: iCAD (ProFound AI): Medical imaging AI vendor focused on mammography and CT with FDA-cleared products. Comparable incumbent in radiology AI commercialization with regulatory depth and clinical evidence.
  • Merative (formerly IBM Watson Health Imaging): Owns 23%+ US PACS imaging market share and distributes Behold.ai's pneumothorax product. Established PACS vendor and channel partner that could also compete with embedded AI capabilities.
  • Siemens Healthineers AI-Rad Companion: Major imaging equipment vendor with embedded AI-Rad Companion platform for chest CT and other modalities. Broad incumbent that competes by integrating AI directly with installed imaging equipment base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Behold.ai social profiles

Digital presence

Behold.ai compliance and trust

Trust signal

Compliance5 records

Behold.ai financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Behold.ai leadership team

Management profile

Number of profiles

Profiles3 records

Behold.ai funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Behold.ai M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Behold.ai

What does Behold.ai do?

Behold.ai develops and sells the red dot® AI-powered diagnostic platform — a Software as a Medical Device that processes chest X-rays and CT head scans to automatically identify normal examinations and triage suspected critical findings (lung cancer, intracranial haemorrhage, acute infarct, pneumothorax). The platform is sold to NHS Trusts in the UK via direct sales and NHS framework contracts, and internationally through channel partners Merative (US) and Apollo Hospitals (India).

Is Behold.ai a public or private company?

Behold.ai is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Behold.ai founded?

Behold.ai was founded in 2017. It employs 1 to 10 people.

Where is Behold.ai based?

Behold.ai is headquartered in London, United Kingdom, in the Europe region.

How does Behold.ai make money?

Two revenue lines are on record. Per Exam Pricing is the primary driver. The others are NHS Framework / Contract Revenue.

Who are Behold.ai's main competitors?

Direct peers on record are Qure.ai, RapidAI, Viz.ai, Annalise.ai, Lunit, Aidoc and Nanox (formerly Zebra Medical Vision). Broad incumbents are Announcement: iCAD (ProFound AI), Merative (formerly IBM Watson Health Imaging) and Siemens Healthineers AI-Rad Companion.

Does Behold.ai have an API?

No public API is recorded for Behold.ai.

What industry is Behold.ai in?

Behold.ai's product category is AI Radiology Diagnostics Software. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Medical FuturistThe Future of Radiology And Artificial IntelligenceThe article discusses the evolving role of artificial intelligence in radiology, arguing that while AI will automate repetitive tasks and assist in diagnosing simpler cases, it will not replace radiologists but rather augment their capabilities. It highlights specific implementations by companies like Behold and Nines, which are using AI to prioritize critical cases such as lung cancer screening and intracranial hemorrhage detection within healthcare systems.openPR.comAI in Radiology Market 18.25% CAGR Outlook Led by Aidoc Medical Ltd AliveCor Arterys Behold Butterfly Network Caption Health Day Zero Diagnostics DiA Imaging Analysis LtdThe AI in radiology market is projected to grow at an 18.25% CAGR from 2025 to 2032, reaching a valuation of about $5 billion. Growth is driven by AI algorithms improving diagnostic accuracy and workflow efficiency, with key players including Aidoc, AliveCor, and GE Healthcare.Digital HealthDigital health startup Behold.ai enters administrationUK-based digital health startup Behold.ai has entered administration after failing to secure any contracts from the government's £21 million AI Diagnostic Fund. CEO Simon Rasalingham has called for an inquiry into the procurement process, alleging that taxpayer money was used to fund overseas competitors like qure.ai while excluding British firms. The company supplies lung cancer AI systems to several NHS organizations and recently won the Prix Galien International award.TradingView6 AI applications already changing the healthcare industryEight AI applications in healthcare are described, including GE Verisound AI for ultrasound imaging, Atomwise for drug discovery, and Behold.ai for radiology. Atomwise identified drug candidates for 235 of 318 targets, and Behold.ai's algorithm achieved 90% accuracy in chest X-ray analysis.CoinTelegraph6 AI applications already changing the healthcare industryEight AI projects are described that are already improving healthcare, including GE Verisound AI for ultrasound imaging, Atomwise for drug discovery, and Behold.ai for radiology. Behold.ai's algorithm achieved 90% accuracy in detecting chest X-ray abnormalities, and Atomwise identified drug candidates for 235 of 318 targets. The article notes AI is accelerating scientific breakthroughs and improving research outcomes.YahooBehold Launches Outfit-driven Shopping PlatformBehold, an outfit-driven shopping app, launches today, combining women's contemporary brands, stylists, and AI. It features 50 brands, charges 25% of each sale, and offers free shipping and returns. The platform will add a blog and editorial content soon.GlobeNewswireBehold.ai partners with Apollo Hospitals Group, India for rapid COVID-19 diagnosis using AI-based chest X-ray technologyBehold.ai partnered with Apollo Hospitals Group for a pilot using its AI chest X-ray triage to diagnose suspected COVID-19. The algorithm will be deployed across 71 hospitals with 12,000 beds, and the service is expected to go live when India's lockdown is eased.GlobeNewswirebehold.ai awarded CE Mark approval for its AI-based chest X-ray diagnosis technologybehold.ai received CE Mark Class IIa certification for its AI-based chest X-ray diagnosis technology, the first such approval. The company estimates the technology could save the NHS over £100m annually by reducing outsourcing costs. The approval also supports COVID-19 triage and backlog reduction.GlobeNewswirebehold.ai awarded CE Mark approval for its AI-based chest X-ray diagnosis technologybehold.ai received CE Mark Class IIa certification for its AI-based chest X-ray diagnosis technology, the first such approval. The company estimates the technology could save the NHS over £100m annually by ruling out normal exams. The approval also supports COVID-19 triage and a national rollout.GlobeNewswirebehold.ai and Wellbeing Software collaborate on national solution for rapid COVID-19 diagnosis using AI analysis of chest X-raysbehold.ai and Wellbeing Software are collaborating to fast-track COVID-19 diagnosis in NHS hospitals using AI analysis of chest X-rays. The solution combines behold.ai's red dot algorithm, which identifies abnormalities in under 30 seconds with over 90% accuracy, and Wellbeing's Cris RIS installed in over 700 locations. A national rollout would help process the high volume of X-rays used for triage.